AlphaWire

newswire

Replimune Shares Surge 127% After FDA Panel Supports Experimental Cancer Therapy

2026-08-01·newswire-us-stock-062835
Replimune Shares Surge 127% After FDA Panel Supports Experimental Cancer Therapy.

Shares of biotechnology company Replimune Group (REPL) soared 127% in after-hours trading Thursday after an independent advisory committee to the U.S. Food and Drug Administration voted 10-3 that key clinical-trial data for the company’s experimental therapy RP1 were reliable and clinically meaningful.

RP1 is being developed for patients with advanced melanoma whose disease progressed after prior anti-PD-1 treatment. The therapy uses a genetically engineered herpes simplex virus backbone designed to directly lyse tumor cells and activate a systemic antitumor immune response.

During the meeting, panel members discussed whether the single-arm trial design could reliably demonstrate the combination therapy’s efficacy and durability. A majority ultimately concluded that the results were sufficient to support the therapy’s potential value. RP1’s path to market has previously encountered setbacks, with the FDA rejecting it twice.

The positive panel outcome marks a key turning point in the application process. Replimune CEO Sushil Patel said the company was encouraged by the result and would continue working with the FDA to advance the review. The FDA is expected to make its final approval decision by Aug. 2, 2026.

#Stocks #Markets

Full text

Replimune Shares Surge 127% After FDA Panel Supports Experimental Cancer Therapy

Shares of biotechnology company Replimune Group (REPL) soared 127% in after-hours trading Thursday after an independent advisory committee to the U.S. Food and Drug Administration voted 10-3 that key clinical-trial data for the company’s experimental therapy RP1 were reliable and clinically meaningful. RP1 is being developed for patients with advanced melanoma whose disease progressed after prior anti-PD-1 treatment. The therapy uses a genetically engineered herpes simplex virus backbone designed to directly lyse tumor cells and activate a systemic antitumor immune response. During the meeting, panel members discussed whether the single-arm trial design could reliably demonstrate the combination therapy’s efficacy and durability. A majority ultimately concluded that the results were sufficient to support the therapy’s potential value. RP1’s path to market has previously encountered setbacks, with the FDA rejecting it twice. The positive panel outcome marks a key turning point in the application process. Replimune CEO Sushil Patel said the company was encouraged by the result and would continue working with the FDA to advance the review. The FDA is expected to make its final approval decision by Aug. 2, 2026.

Shares of biotechnology company Replimune Group (REPL) soared 127% in after-hours trading Thursday after an independent advisory committee to the U.S. Food and Drug Administration voted 10-3 that key clinical-trial data for the company’s experimental therapy RP1 were reliable and clinically meaningful.

RP1 is being developed for patients with advanced melanoma whose disease progressed after prior anti-PD-1 treatment. The therapy uses a genetically engineered herpes simplex virus backbone designed to directly lyse tumor cells and activate a systemic antitumor immune response.

During the meeting, panel members discussed whether the single-arm trial design could reliably demonstrate the combination therapy’s efficacy and durability. A majority ultimately concluded that the results were sufficient to support the therapy’s potential value.

RP1’s path to market has previously encountered setbacks, with the FDA rejecting it twice. The positive panel outcome marks a key turning point in the application process. Replimune CEO Sushil Patel said the company was encouraged by the result and would continue working with the FDA to advance the review.

The FDA is expected to make its final approval decision by Aug. 2, 2026.

← Back to archive